ArticlePLoS pathogens2025
Identification of a Kingella kingae factor H binding protein that is the major determinant of serum resistance.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GM000287 is a conserved determinant of serum resistance and virulence in Klebsiella pneumoniae.PLoS pathogens · 2026Article
- An Evaluation of Novel Inflammatory Biomarkers in Children withPathogens (Basel, Switzerland) · 2026Article
- It is time to have a molecular test for diagnosingJournal of clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Kingella kingae is a Gram-negative bacterium that has emerged as a leading cause of invasive disease in children between 6 months and 4 years of age. K. kingae initiates infection by colonizing the oropharynx, then breaches the oropharyngeal epithelium, enters the bloodstream, and disseminates to distant sites to cause disease, including osteomyelitis, septic arthritis, and endocarditis. To survive in the bloodstream and disseminate to sites of invasive disease, K. kingae produces a polysaccharide capsule and an exopolysaccharide that inhibit opsonin deposition and mediate resistance to complement-mediated serum killing. However, elimination of these extracellular polysaccharides only partially reduces K. kingae survival in human serum, suggesting that additional factors contribute to serum resistance. In this study, we found that K. kingae binds human factor H (FH), a negative regulator of the alternative complement pathway. In experiments using rat serum as a source of complement, we observed that K. kingae was able to utilize human FH to resist killing. Introduction of exogenous human FH into the juvenile rat infection model of K. kingae disease enhanced virulence in vivo, demonstrating the importance of FH binding in the pathogenesis of disease. Far-western blot analysis identified a 37-kDa outer membrane protein designated KK02920 that was responsible for FH binding and enhanced virulence in vivo in the presence of human FH. Loss of KK02920 virtually abrogated serum resistance, indicating that KK02920 is the major determinant of K. kingae serum resistance. Additional analysis revealed the presence of KK02920 across a collection of serum-resistant invasive and carrier K. kingae isolates, all of which can utilize human FH to resist complement-mediated killing. This work demonstrates the importance of a complement-regulator binding protein as a major mechanism of serum resistance in an encapsulated organism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.